• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本慢性肾脏病全球改善预后组织(KDIGO)热图所示的心血管、肾脏及死亡风险

Cardiovascular, renal and mortality risk by the KDIGO heatmap in Japan.

作者信息

Maruyama Shoichi, Tanaka Tetsuhiro, Akiyama Hiroki, Hoshino Mitsuru, Inokuchi Shoichiro, Kaneko Shuji, Shimamoto Koji, Ozaki Asuka

机构信息

Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Department of Nephrology, Tohoku University Graduate School of Medicine, Sendai, Japan.

出版信息

Clin Kidney J. 2024 Jul 30;17(8):sfae228. doi: 10.1093/ckj/sfae228. eCollection 2024 Aug.

DOI:10.1093/ckj/sfae228
PMID:39170932
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11336683/
Abstract

BACKGROUND

This study aimed to assess the prognosis of people with chronic kidney disease (CKD) in Japan using the Kidney Disease: Improving Global Outcomes (KDIGO) heatmap.

METHODS

The prognoses of individuals with estimated glomerular filtration rates (eGFR) <90 mL/min/1.73 m were evaluated based on the KDIGO heatmap using an electronic medical record database in Japan. The primary outcome was major adverse cardiovascular events (MACE), a composite of myocardial infarction (MI), stroke, heart failure (HF) hospitalization and in-hospital death (referred to as MACE1). Additionally, MACE2 (MI hospitalization, stroke hospitalization, HF hospitalization and in-hospital death) was examined. The secondary outcome was the renal outcome.

RESULTS

Of the 543 606 individuals included, the mean age was 61.6 ± 15.3 years, 50.1% were male and 40.9% lacked urine protein results. The risk of MACEs increased independently with both eGFR decline and increasing proteinuria from the early KDIGO stages: hazard ratios (95% confidence interval) of MACE1 and MACE2, compared with G2A1 were 1.16 (1.12-1.20) and 1.17 (1.11-1.23), respectively, for G3aA1, and 1.17 (1.12-1.21) and 1.35 (1.28-1.43), respectively, for G2A2. This increased up to 2.83 (2.54-3.15) and 3.43 (3.00-3.93), respectively, for G5A3. Risks of renal outcomes also increased with CKD progression.

CONCLUSIONS

This study is the first to demonstrate the applicability of the KDIGO heatmap in assessing cardiovascular and renal risk in Japan. The risk increased from the early stages of CKD, indicating the importance of early diagnosis and intervention through appropriate testing.

摘要

背景

本研究旨在使用改善全球肾脏病预后(KDIGO)热图评估日本慢性肾脏病(CKD)患者的预后。

方法

在日本,利用电子病历数据库,基于KDIGO热图对估算肾小球滤过率(eGFR)<90 mL/min/1.73 m²的个体的预后进行评估。主要结局是主要不良心血管事件(MACE),它是心肌梗死(MI)、中风、心力衰竭(HF)住院和院内死亡的复合事件(称为MACE1)。此外,还对MACE2(MI住院、中风住院、HF住院和院内死亡)进行了检查。次要结局是肾脏结局。

结果

纳入的543606名个体中,平均年龄为61.6±15.3岁,50.1%为男性,40.9%缺乏尿蛋白结果。从KDIGO早期阶段开始,MACE的风险随eGFR下降和蛋白尿增加而独立升高:与G2A1相比,G3aA1的MACE1和MACE2的风险比(95%置信区间)分别为1.16(1.12 - 1.20)和1.17(1.11 - 1.23),G2A2的分别为1.17(1.12 - 1.21)和1.35(1.28 - 1.43)。到G5A3时,分别增至2.83(2.54 - 3.15)和3.43(3.00 - 3.93)。肾脏结局的风险也随CKD进展而增加。

结论

本研究首次证明了KDIGO热图在评估日本心血管和肾脏风险方面的适用性。风险从CKD早期阶段就开始增加,这表明通过适当检测进行早期诊断和干预的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c50d/11336683/26515ffbc995/sfae228fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c50d/11336683/9844a729ffe2/sfae228fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c50d/11336683/26515ffbc995/sfae228fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c50d/11336683/9844a729ffe2/sfae228fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c50d/11336683/26515ffbc995/sfae228fig2.jpg

相似文献

1
Cardiovascular, renal and mortality risk by the KDIGO heatmap in Japan.日本慢性肾脏病全球改善预后组织(KDIGO)热图所示的心血管、肾脏及死亡风险
Clin Kidney J. 2024 Jul 30;17(8):sfae228. doi: 10.1093/ckj/sfae228. eCollection 2024 Aug.
2
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.卡格列净在 KDIGO 风险类别中的心血管和肾脏结局的相对和绝对风险降低:CANVAS 计划的结果。
Am J Kidney Dis. 2021 Jan;77(1):23-34.e1. doi: 10.1053/j.ajkd.2020.06.018. Epub 2020 Sep 21.
3
Population characteristics and diagnosis rate of chronic kidney disease by eGFR and proteinuria in Japanese clinical practice: an observational database study.日本临床实践中慢性肾脏病按估算肾小球滤过率和蛋白尿的人群特征及诊断率:一项观察性数据库研究
Sci Rep. 2024 Mar 2;14(1):5172. doi: 10.1038/s41598-024-55827-7.
4
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.达格列净对不同基线 KDIGO 风险类别的肾脏和心血管结局的影响:DAPA-CKD 试验的事后分析。
Diabetologia. 2022 Jul;65(7):1085-1097. doi: 10.1007/s00125-022-05694-6. Epub 2022 Apr 21.
5
Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure.沙库巴曲缬沙坦在心力衰竭患者肾功能损害谱中的作用。
J Am Coll Cardiol. 2024 Jun 4;83(22):2148-2159. doi: 10.1016/j.jacc.2024.03.392. Epub 2024 Apr 6.
6
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial.恩格列净与 KDIGO 风险类别心血管和肾脏结局:一项随机、双盲、安慰剂对照、多国试验分析。
Clin J Am Soc Nephrol. 2020 Oct 7;15(10):1433-1444. doi: 10.2215/CJN.14901219. Epub 2020 Sep 29.
7
Chronic Kidney Disease Stage and Cardiovascular and Mortality Events Among Older Adults: The SPRINT Trial.老年人慢性肾脏病分期与心血管及死亡事件:收缩压干预试验(SPRINT)
Kidney Med. 2024 May 18;6(7):100845. doi: 10.1016/j.xkme.2024.100845. eCollection 2024 Jul.
8
Identification and outcomes of KDIGO-defined chronic kidney disease in 1.4 million U.S. Veterans with heart failure.在美国 140 万心力衰竭退伍军人中识别和评估 KDIGO 定义的慢性肾脏病及其结局。
Eur J Heart Fail. 2024 May;26(5):1251-1260. doi: 10.1002/ejhf.3210. Epub 2024 May 3.
9
Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.钠-葡萄糖共转运蛋白 2 抑制剂根据肾功能对心血管和肾脏结局的差异影响:涉及 10 项随机临床试验和 71553 人的剂量反应荟萃分析。
Eur J Endocrinol. 2023 Jul 20;189(1):S17-S25. doi: 10.1093/ejendo/lvad078.
10
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂在患有早期(1 至 3 期)非糖尿病慢性肾脏病的成人中的应用。
Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD007751. doi: 10.1002/14651858.CD007751.pub3.

引用本文的文献

1
Cost-Effectiveness Analysis of SGLT2 Inhibitors for Cardio-Renal-Metabolic Disease Based on Data from Japanese Studies.基于日本研究数据的SGLT2抑制剂治疗心肾代谢疾病的成本效益分析。
Adv Ther. 2025 Jun;42(6):2888-2905. doi: 10.1007/s12325-025-03157-z. Epub 2025 Apr 29.

本文引用的文献

1
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.KDIGO 2024慢性肾脏病评估与管理临床实践指南
Kidney Int. 2024 Apr;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018.
2
Population characteristics and diagnosis rate of chronic kidney disease by eGFR and proteinuria in Japanese clinical practice: an observational database study.日本临床实践中慢性肾脏病按估算肾小球滤过率和蛋白尿的人群特征及诊断率:一项观察性数据库研究
Sci Rep. 2024 Mar 2;14(1):5172. doi: 10.1038/s41598-024-55827-7.
3
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
非奈利酮减少蛋白尿对 2 型糖尿病患者慢性肾脏病结局的影响:中介分析。
Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5.
4
Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.估算肾小球滤过率、白蛋白尿与不良结局:一项个体参与者数据的荟萃分析。
JAMA. 2023 Oct 3;330(13):1266-1277. doi: 10.1001/jama.2023.17002.
5
Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme.全球慢性肾脏病相关经济负担:针对 Inside CKD 研究计划医疗费用的实用综述。
Adv Ther. 2023 Oct;40(10):4405-4420. doi: 10.1007/s12325-023-02608-9. Epub 2023 Jul 26.
6
Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study.法国、德国、意大利、日本和美国未确诊的 3 期慢性肾脏病的患病率:来自多国观察性 REVEAL-CKD 研究的结果。
BMJ Open. 2023 May 22;13(5):e067386. doi: 10.1136/bmjopen-2022-067386.
7
Patient Management and Clinical Outcomes Associated with a Recorded Diagnosis of Stage 3 Chronic Kidney Disease: The REVEAL-CKD Study.与记录的 3 期慢性肾脏病诊断相关的患者管理和临床结局:REVEAL-CKD 研究。
Adv Ther. 2023 Jun;40(6):2869-2885. doi: 10.1007/s12325-023-02482-5. Epub 2023 May 3.
8
Empagliflozin in Patients with Chronic Kidney Disease.恩格列净在慢性肾脏病患者中的应用。
N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4.
9
Stroke incidence and chronic kidney disease: A hospital-based prospective cohort study.卒中发病率与慢性肾脏病:一项基于医院的前瞻性队列研究。
Nephrology (Carlton). 2022 Jul;27(7):577-587. doi: 10.1111/nep.14049. Epub 2022 May 9.
10
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.非奈利酮治疗的肾脏结局:FIGARO-DKD 研究分析。
Nephrol Dial Transplant. 2023 Feb 13;38(2):372-383. doi: 10.1093/ndt/gfac157.